Treatment of premenstrual dysphoric disorder with luteal phase dosing of sertraline.

Abstract:

:Sertraline (Zoloft, Pfizer Inc.) is a selective serotonin re-uptake inhibitor (SSRI) which has been approved by the US FDA for the treatment of premenstrual dysphoric disorder (PMDD). PMDD is a severe form of premenstrual syndrome (PMS) which affects at least 5 - 8% of women of reproductive age. It is characterised by cyclic appearance at the late luteal phase of the menstrual cycle, and disappearance following the beginning of menses, with no symptoms during at least 1 week of the cycle - usually during the mid-follicular phase. Due to the cyclic luteal occurrence of PMDD, luteal phase dosing of SSRIs has been suggested and proven effective for sertraline as well as several other SSRIs. The clinical response of sertraline is reported to be within several days following initiation of treatment. Despite repeated cyclic discontinuation, no significant discontinuation adverse effects have been reported. In addition to its proven clinical efficacy, luteal-phase dosing may offer the advantages of minimising adverse effects of SSRIs while reducing the personal and economic burden of taking a prescription medication continuously for long periods and thus increasing compliance.

authors

Halbreich U,Kahn LS

doi

10.1517/14656566.4.11.2065

keywords:

subject

Has Abstract

pub_date

2003-11-01 00:00:00

pages

2065-78

issue

11

eissn

1465-6566

issn

1744-7666

journal_volume

4

pub_type

杂志文章,评审
  • Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects.

    abstract:INTRODUCTION:Benign prostate hyperplasia (BPH) is one of the most prevalent diseases in aging men. It may adversely affect quality-of-life due to the presence of low urinary tract symptoms (LUTS) and its effects on sexuality. AREAS COVERED:The impact of α1-blockers, 5α-reductase inhibitors (5-ARI), and phosphodiestera...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2020.1817382

    authors: La Vignera S,Aversa A,Cannarella R,Condorelli RA,Duca Y,Russo GI,Calogero AE

    更新日期:2020-09-09 00:00:00

  • Pharmacoeconomic considerations in anticoagulant drug use.

    abstract::Anticoagulants are used for the prevention and treatment of venous thromboembolism and for the secondary prevention of stroke and myocardial infarction. The list of available anticoagulants includes unfractionated heparin, low molecular weight heparins, fondaparinux, warfarin and the direct thrombin inhibitors. Numero...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.8.989

    authors: Hawkins D,Huston SA

    更新日期:2006-06-01 00:00:00

  • Adjunctive strategies in the treatment of refractory bipolar depression: clinician options in the absence of a systematic database.

    abstract::Multiple approaches to enhancing antidepressant treatment response in bipolar depression are available and should, in many instances, be explored despite a lack of definitive controlled trial literature supporting their efficacy. Given that the morbidity of depression is three times greater than mania in bipolar illne...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.4.531

    authors: Post RM

    更新日期:2005-04-01 00:00:00

  • Pharmacotherapy in inherited and acquired ventricular arrhythmia in structurally normal adult hearts.

    abstract::Introduction: Ventricular arrhythmias are often seen in association with structural heart disease. However, approximately a tenth of affected patients have apparently normal hearts, where such arrhythmias typically occur in young patients, are sometimes inherited and can occasionally lead to sudden cardiac death (SCD)...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1669561

    authors: Ortmans S,Daval C,Aguilar M,Compagno P,Cadrin-Tourigny J,Dyrda K,Rivard L,Tadros R

    更新日期:2019-12-01 00:00:00

  • Oral valproic acid for epilepsy--long-term experience in therapy and side effects.

    abstract::Valproic acid (VPA) is considered to be a drug of first choice and one of the most frequently-prescribed antiepileptic drugs worldwide for the therapy of generalized and focal epilepsies, including special epileptic. It is a broad-spectrum antiepileptic drug and is usually well tolerated. Rarely, serious complications...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.2.285

    authors: Gerstner T,Bell N,König S

    更新日期:2008-02-01 00:00:00

  • Current and up-and-coming pharmacotherapy for obsessive-compulsive disorder in adults.

    abstract:INTRODUCTION:Only 40-60% of obsessive-compulsive patients respond to first line treatments, such as selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioral therapy. Several second-line treatments have been investigated in the last two decades, and most of them seem to work, at least in a subset of pati...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1528230

    authors: Grassi G,Pallanti S

    更新日期:2018-10-01 00:00:00

  • Alprazolam extended-release in panic disorder.

    abstract::Alprazolam-XR is an extended-release formulation of alprazolam designed to deliver sustained therapeutic concentrations for 24 h after once-daily dosing. Plasma concentrations gradually decline as the time for the next dose approaches, but still remain above therapeutic minimum levels. The anti-panic efficacy of alpra...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 临床试验,杂志文章

    doi:10.1517/14656566.5.7.1599

    authors: Rickels K

    更新日期:2004-07-01 00:00:00

  • Oral healthcare for HIV-infected patients: an international perspective.

    abstract::The orofacial complications of HIV infection are diverse, include opportunistic infection and malignancy and in many instances are region specific. Although effective management strategies to treat HIV-associated oral disease have been developed in North America and Europe, the evidence base on which these rely remain...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.3.387

    authors: Hegarty AM,Chaudhry SI,Hodgson TA

    更新日期:2008-02-01 00:00:00

  • Itraconazole.

    abstract::Itraconazole is a broad spectrum triazole antifungal agent. It has favourable pharmacodynamic and pharmacokinetic profiles and is available as both oral and i.v. formulations. Over the last two decades, clinical and animal infection studies have demonstrated the efficacy of itraconazole in a wide range of superficial ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.1.2.287

    authors: Piérard GE,Arrese JE,Piérard-Franchimont C

    更新日期:2000-01-01 00:00:00

  • Hydrochlorothiazide: is it a wise choice?

    abstract:INTRODUCTION:Hydrochlorothiazide (HCTZ) has not been shown to reduce mortality or cardiovascular events when given as a single agent. In fact, HCTZ increased cardiovascular death and coronary artery disease (CAD) compared to placebo and usual care in 2 randomized trials, yet it is the most prescribed diuretic in the Un...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.670636

    authors: DiNicolantonio JJ

    更新日期:2012-04-01 00:00:00

  • Etravirine: the renaissance of non-nucleoside reverse transcriptase inhibitors.

    abstract:BACKGROUND:Etravirine is the first non-nucleoside reverse transcriptase inhibitor (NNRTI) to be active against human immunodeficiency virus with NNRTI mutations. OBJECTIVE:To understand the unique features of etravirine and to evaluate its safety, efficacy, and optimal use. METHODS:The structure and the mechanism of ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656560802489569

    authors: Jayaweera DT,Espinoza L,Castro J

    更新日期:2008-12-01 00:00:00

  • Current concepts in the pharmacotherapy of benign prostatic hyperplasia.

    abstract::Benign prostatic hyperplasia is a major men's health issue, with approximately 80% of all men developing this condition within their lifetime. A variety of oral treatments is available, including alpha-adrenoceptor antagonists (alpha-blockers), 5alpha reductase inhibitors, aromatase inhibitors and phytotherapy. A larg...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.3.12.1727

    authors: Khastgir J,Arya M,Shergill IS,Kalsi JS,Minhas S,Mundy AR

    更新日期:2002-12-01 00:00:00

  • Sofosbuvir + velpatasvir + voxilaprevir for the treatment of hepatitis C infection.

    abstract:INTRODUCTION:Hepatitis C is a disease with a significant global impact. Over the last several years, the treatment of the disease has been revolutionized. Therapy has transformed over the last several years with the approval of second generation direct acting antivirals, and currently utilized medications for the treat...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2018.1459567

    authors: Cory TJ,Mu Y,Gong Y,Kodidela S,Kumar S

    更新日期:2018-05-01 00:00:00

  • Recommendations for the management of migraine in paediatric patients.

    abstract::Migraine is a common and disabling condition in children and adolescents. The complexity of migraine on a pathogenetic and clinical level results from the interaction between biological, psychological and environmental factors. Appropriate management requires an individually tailored strategy giving due consideration ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.6.731

    authors: Balottin U,Termine C

    更新日期:2007-04-01 00:00:00

  • Evolving simplified treatment strategies for HIV infection: the role of a single-class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir.

    abstract::Simplified antiretroviral regimens have been developed with the aim of improving treatment adherence and quality of life of HIV-infected patients. The single-class triple-nucleoside reverse transcriptase inhibitor combination has contributed to the improvement of the management of HIV infection, especially in patients...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.16.2233

    authors: Mastroianni CM,d'Ettorre G,Vullo V

    更新日期:2006-11-01 00:00:00

  • Treatment options for chronic myeloid leukemia.

    abstract:INTRODUCTION:The bcr-abl tyrosine kinase inhibitors (TKIs) are the cornerstone treatment for chronic myeloid leukemia (CML). However, there are many topics related to therapy that remain debated. AREAS COVERED:The aim of this paper is to give the reader a comprehensive review of how to treat CML at diagnosis, how to m...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.671296

    authors: Tanaka MF,Kantarjian H,Cortes J,Ohanian M,Jabbour E

    更新日期:2012-04-01 00:00:00

  • Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C.

    abstract:INTRODUCTION:Chronic hepatitis C infection is a global disease with 160 million people infected worldwide. Until recently, therapy was characterized by long duration, suboptimal success rates and significant adverse drug reactions. The development of direct-acting antivirals initiated a dramatic change in the treatment...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.972364

    authors: Stirnimann G

    更新日期:2014-12-01 00:00:00

  • Amyloidosis and POEMS syndrome.

    abstract:IMPORTANCE OF THE FIELD:Treatment options for amyloidosis and polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome have rapidly increased in the past years, but many patients are diagnosed late in the disease course and do not receive state-of-the art therapy. AREAS COVERED IN THI...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656561003769874

    authors: Chee CE,Dispenzieri A,Gertz MA

    更新日期:2010-06-01 00:00:00

  • Drug interactions in the management of HIV infection.

    abstract::The availability of antiretroviral therapy has significantly reduced the morbidity and mortality of HIV infection. In addition, improved treatment of opportunistic infections and comorbidities common to patients with HIV is further prolonging the lives of patients. Improvement in the treatment of HIV has led to a sign...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.2.233

    authors: Robertson SM,Penzak SR,Pau AK

    更新日期:2005-02-01 00:00:00

  • Synthetic pharmacotherapy for lupus nephritis.

    abstract:INTRODUCTION:Lupus nephritis is a frequent complication and a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). Area covered: The main characteristics and mechanisms of action of the synthetic drugs more frequently used in lupus nephritis are described. Possible strategies aime...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1276563

    authors: Moroni G,Ponticelli C

    更新日期:2017-02-01 00:00:00

  • Pegaptanib sodium for the treatment of age-related macular degeneration.

    abstract:BACKGROUND:Pegaptanib sodium, the first aptamer therapeutic approved for use and the first antiangiogenic agent used to treat ocular neovascular disease, acts by inhibiting the 165 isoform of vascular endothelial growth factor believed primarily responsible for pathologic ocular neovascularization and vascular permeabi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.3.499

    authors: Apte RS

    更新日期:2008-02-01 00:00:00

  • Pharmacotherapy for knee osteoarthritis: current and emerging therapies.

    abstract:INTRODUCTION:Osteoarthritis (OA) is the leading cause of pain, loss of function and disability in the elderly, with the knee being the most impactful joint affected. Currently, there is still no 'cure' in OA treatment. AREAS COVERED:The authors review the current and emerging therapies for knee OA including traditiona...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1732924

    authors: Cao P,Li Y,Tang Y,Ding C,Hunter DJ

    更新日期:2020-05-01 00:00:00

  • Advances in pharmacotherapy for hyperphosphatemia in renal disease.

    abstract:INTRODUCTION:Hyperphosphatemia in chronic kidney disease (CKD) is considered as an independent risk factor for surrogate clinical end points like vascular calcification (VC) and bone disease, or hard clinical outcomes like cardiovascular events. Various treatment options are available for phosphate removal or reduction...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1092521

    authors: Spasovski G

    更新日期:2015-01-01 00:00:00

  • Combination of glibenclamide-metformin HCl for the treatment of type 2 diabetes mellitus.

    abstract:INTRODUCTION:Combination of glibenclamide (glyburide in the U.S.) and metformin hydrochloride simultaneously addresses two different but complimentary mechanisms to improve glycemic control in type 2 diabetes. AREAS COVERED:The pharmacokinetics, efficacy, and side effect profile of the oral combination of glibenclamid...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.738196

    authors: Lamos EM,Stein SA,Davis SN

    更新日期:2012-12-01 00:00:00

  • Long-term oral carvedilol in chronic heart failure.

    abstract::The long-term beta-blockade strategy with carvedilol, metoprolol succinate or bisoprolol is now strongly recommended to reduce the rates of mortality and morbidity in patients with chronic heart failure (CHF). Although the benefits observed with such drugs are viewed as a class effect, theoretically, carvedilol might ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.5.6.1359

    authors: Di Lenarda A,Sabbadini G,Moretti M,Sinagra G

    更新日期:2004-06-01 00:00:00

  • Efavirenz: a review.

    abstract::Efavirenz is a non-nucleoside reverse transcriptase inhibitor that in most treatment guidelines is recommended to be taken combined with two nucleoside analogue reverse transcriptase inhibitors, as a preferred first-line regimen for the treatment of HIV-1 infection. The antiretroviral efficacy of efavirenz-based combi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.6.851

    authors: Vrouenraets SM,Wit FW,van Tongeren J,Lange JM

    更新日期:2007-04-01 00:00:00

  • Advancing treatment options for chronic idiopathic constipation.

    abstract:INTRODUCTION:Chronic constipation is a global problem affecting all ages and associated with considerable morbidity and significant financial burden for society. Though formerly defined on the basis of a single symptom, infrequent defecation; constipation is now viewed as a syndrome encompassing several complaints such...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2016.1127356

    authors: Quigley EM,Neshatian L

    更新日期:2016-01-01 00:00:00

  • Irinotecan and bevacizumab in recurrent glioblastoma multiforme.

    abstract:INTRODUCTION:Glioblastoma multiforme (GBM) is the most common high grade primary brain tumor in adults. Despite significant advances in treatment, the prognosis remains poor. Bevacizumab (BVZ) and irinotecan (CPT-11) are currently being investigated in the treatment of GBM patients. Although treatment with BVZ and irin...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.566558

    authors: Jakobsen JN,Hasselbalch B,Stockhausen MT,Lassen U,Poulsen HS

    更新日期:2011-04-01 00:00:00

  • Pharmacotherapy for the prevention of malaria in pregnant women: currently available drugs and challenges.

    abstract:INTRODUCTION:Malaria in pregnancy continues to be a significant public health burden globally, with over 100 million women at risk each year. Sulfadoxine-pyrimethamine (SP) is the only antimalarial recommended for intermittent preventive therapy in pregnancy (IPTp) but increasing parasite resistance threatens its viabi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1526923

    authors: Moore BR,Davis TME

    更新日期:2018-11-01 00:00:00

  • Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.

    abstract:INTRODUCTION:Increasing population age, obesity and physical inactivity mean that type 2 diabetes mellitus (T2DM) is increasingly common. Current treatments may be limited by adverse events, drug-drug interactions or contraindication/need for dose adjustment in patients with renal impairment. AREAS COVERED:This paper ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.642863

    authors: Forst T,Pfützner A

    更新日期:2012-01-01 00:00:00